Novozymes A/S
Other OTCTotal Valuation
Novozymes A/S carries a market capitalization of 26.81B, placing it among publicly traded companies globally. Its enterprise value stands at 176.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 26.81B |
| Enterprise Value | 176.19B |
Share Statistics
Novozymes A/S currently has 466.23M shares outstanding.
| Shares Outstanding | 466.23M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Novozymes A/S trades at a trailing price-to-earnings ratio of 377.83. The price-to-sales ratio is 55.29, and the price-to-book ratio stands at 15.45.
| PE Ratio | 377.83 |
| PS Ratio | 55.29 |
| PB Ratio | 15.45 |
| P/TBV Ratio | -789.93 |
| P/FCF Ratio | 143.00 |
| P/OCF Ratio | 212.55 |
Enterprise Valuation
On an enterprise value basis, Novozymes A/S trades at an EV/EBITDA multiple of 258.73 and an EV/FCF ratio of 144.73. The EV/Sales ratio of 56.21 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 258.73 provides insight into valuation relative to core operating earnings.
| EV / Sales | 56.21 |
| EV / EBITDA | 258.73 |
| EV / EBIT | 258.73 |
| EV / FCF | 144.73 |
Financial Position
Novozymes A/S maintains a current ratio of 1.67, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.67 |
| Quick Ratio | 0.27 |
| Debt / Equity | 29.42 |
| Debt / EBITDA | 4.72 |
| Interest Coverage | N/A |
Financial Efficiency
Novozymes A/S posts a return on equity of 8.18 and a return on invested capital of 7.51.
| Return on Equity (ROE) | 8.18 |
| Return on Assets (ROA) | 5.55 |
| Return on Invested Capital (ROIC) | 7.51 |
| Return on Capital Employed (ROCE) | 6.36 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.52 |
Taxes
Over the trailing twelve months, Novozymes A/S has paid 125.40M in income taxes, reflecting an effective tax rate of 21.47.
| Income Tax | 125.40M |
| Effective Tax Rate | 21.47 |
Stock Price Statistics
Novozymes A/S's stock has declined approximately -20.19431% over the past 52 weeks. The 50-day moving average sits at 58.82, while the 200-day moving average is 60.80.
| Beta (5Y) | N/A |
| 52-Week Price Change | -20.19431% |
| 50-Day Moving Average | 58.82 |
| 200-Day Moving Average | 60.80 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Novozymes A/S generated 3.13B in revenue and converted that into 458.70M in net income, yielding earnings per share of 0.98. EBITDA reached 681.00M, while operating income came in at 681.00M.
| Revenue | 3.13B |
| Gross Profit | 1.74B |
| Operating Income | 681.00M |
| Pretax Income | 584.10M |
| Net Income | 458.70M |
| EBITDA | 681.00M |
| EBIT | 681.00M |
| Earnings Per Share (EPS) | 0.98 |
Balance Sheet
Novozymes A/S holds 329.40M in cash and equivalents against 3.21B in total debt, resulting in a net debt position of 2.89B. Total book value stands at 11.22B, with working capital of 823.30M providing operational flexibility.
| Cash & Cash Equivalents | 329.40M |
| Total Debt | 3.21B |
| Net Debt | 2.89B |
| Equity (Book Value) | 11.22B |
| Book Value Per Share | 24.00 |
| Working Capital | 823.30M |
Cash Flow
Novozymes A/S produced 815.40M in operating cash flow over the past twelve months. After subtracting -402.00M in capital expenditures, free cash flow totaled 413.40M - equivalent to 0.88 per share.
| Operating Cash Flow | 815.40M |
| Capital Expenditures | -402.00M |
| Free Cash Flow | 413.40M |
| FCF Per Share | 0.88 |
Margins
Novozymes A/S operates with a gross margin of 55.45, reflecting its pricing power and cost economics. The operating margin of 21.73 and net profit margin of 14.63 provide insight into operational efficiency.
| Gross Margin | 55.45 |
| Operating Margin | 21.73 |
| Pretax Margin | 18.64 |
| Profit Margin | 14.63 |
| EBITDA Margin | 21.73 |
Dividends & Yields
The company's payout ratio of 115.00 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 1.13 |
| Dividend Yield | N/A |
| Payout Ratio | 115.00 |
| Shareholder Yield | -0.68 |
| FCF Yield | 0.70 |
Stock Splits
Novozymes A/S's most recent stock split took place on November 28, 2011 with a 1:5 split ratio.
| Last Split Date | 11/28/2011 |
| Split Ratio | 1:5 |
Scores
Novozymes A/S posts an Altman Z-Score of 22.62, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 22.62 |